Diagnostic performance of the fully automated Roche Elecsys SARS-CoV-2 antigen electrochemiluminescence immunoassay: a pooled analysis

Clinical Chemistry and Laboratory Medicine (CCLM), Journal Year: 2022, Volume and Issue: 60(5), P. 655 - 661

Published: Feb. 3, 2022

Abstract Objectives Among the diagnostic tests that have recently become commercially available for diagnosing coronavirus disease 2019 (COVID-19), fully-automated Roche Elecsys severe acute respiratory syndrome 2 (SARS-CoV-2) antigen electrochemiluminescence immunoassay (ECLIA) is one of most widespread its adaptability within a system laboratory automation, rapidity and high-throughput. This article aimed to provide results first pooled analysis accuracy SARS-CoV-2 infections. Content We carried out an electronic search in Scopus Medline, without language or date restrictions (i.e., up January 18, 2022), identify articles where performance ECLIA was compared with reference molecular techniques. Summary Overall, 11 studies were identified, 10 which (n=6,095 swabs) provided necessary data inclusion analysis. The sensitivity, specificity area under curve (AUC) nasopharyngeal samples 0.68 (95%CI, 0.66–0.70), 0.99 0.99–0.99) 0.958 0.936–0.980), respectively. cumulative observed agreement assays 89.5% kappa statistic 0.735 0.716–0.754). sensitivity high viral load cycle threshold values <28–30) 0.95 0.92–0.97). Outlook this confirm has optimal identifying higher load, thus making it reliable technique mass screening supporting strategies based on shorten isolation and/or quarantine.

Language: Английский

---

Mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice

Microbial Cell Factories, Journal Year: 2023, Volume and Issue: 22(1)

Published: May 9, 2023

The use of probiotic lactic acid bacteria as a mucosal vaccine vector is considered promising alternative compared to the other microorganisms because its "Generally Regarded Safe" status, potential adjuvant properties, and tolerogenicity host. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes disease (COVID-19), highly transmissible pathogenic. This study aimed determine Lactiplantibacillus plantarum expressing SARS-CoV-2 epitopes against SARS-CoV-2.In this study, possible antigenic determinants spike (S1-1, S1-2, S1-3, S1-4), membrane (ME1 ME2), envelope (E) proteins were predicted, recombinant L. strains surface-displaying these constructed. Subsequently, immune responses induced by in vitro vivo. Most surface-displayed pro-inflammatory cytokines [tumor necrosis factor alpha (TNF-α interleukin (IL)-6] anti-inflammatory (IL-10) lipopolysaccharide-induced RAW 264.7, with highest cytokine ratio S1-1 S1-2 groups, followed that S1-3 group. When orally administered mice, all most increased expression IL-4, along levels TNF-α, interferon-gamma, IL-10, specifically protein groups. Thus, surface from S1 showed immunoregulatory effects, suggesting ability potentially circumvent hyperinflammatory states relevant monocyte/macrophage cell activation. At 35 days post immunization (dpi), serum IgG marked increase S1-1, Fecal IgA significantly 21 dpi antigen but boosting effect after was explicitly observed oral administration antigens into mice significant humoral responses.This suggests can effectively deliver intestinal sites could serve novel approach for development.

Language: Английский

---

Nasal delivery of encapsulated recombinant ACE2 as a prophylactic drug for SARS-CoV-2

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 655, P. 124009 - 124009

Published: March 16, 2024

Angiotensin-converting enzyme 2 (ACE2) is responsible for cell fusion with SARS-CoV viruses. ACE2 contained in different areas of the human body, including nasal cavity, which considered main entrance types airborne We took advantage roles and cavity SARS-CoV-2 replication transmission to develop a dry powder. Recombinant (rhACE2), after proper encapsulation achieved via spray freeze drying, shows binding efficiency spike proteins higher than 77 % at quantities lower 5 µg/ml. Once delivered nose, encapsulated rhACE2 led viability permeability RPMI 2650 cells least 90.20 ± 0.67 47.96 4.46 %, respectively, concentrations 1 mg/ml. These results were validated using powder containing prevent or treat infections derived from SARS-CoV-2.

Language: Английский

---

Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals

Clinical Chemistry and Laboratory Medicine (CCLM), Journal Year: 2022, Volume and Issue: 60(6), P. 930 - 933

Published: March 18, 2022

We provide here an updated analysis of ongoing serosurveillance study, presenting data on the effect a third dose Pfizer/BioNTech BNT162b2 vaccine serum anti-SARS-CoV-2 IgG antibodies.We tested baseline SARS-CoV-2 seronegative healthcare workers undergoing primary vaccination with mRNA-based COVID-19 Comirnaty vaccine, followed by administration homologous booster (third dose). Venous blood was collected before either vaccination, at 1, 3 and 6 months afterwards, as well 1 month after receiving booster. The concentration assayed DiaSorin Trimeric spike immunoassay.The final study population included 53 (median age 46 years; 60% females). A first peak trimeric values reached completing which levels gradually declined until second observed (8,700 kBAU/L), 39-fold higher than (221 kBAU/L; p<0.001), but also nearly threefold compared to seen (2,990 p<0.001). rate subjects protective (i.e., >264 kBAU/L) increased from 47.2% 100% booster.These results support current policies fostering boosters reinforce humoral immunity against SARS-CoV-2.

Language: Английский

---

Effects of Recombinant SARS-CoV-2 Spike Protein Variants on Platelet Morphology and Activation

Seminars in Thrombosis and Hemostasis, Journal Year: 2023, Volume and Issue: 50(02), P. 275 - 283

Published: June 16, 2023

Abstract Platelets are central elements of hemostasis and also play a pivotal role in the pathogenesis thrombosis coronavirus disease 2019. This study was planned to investigate effects different severe acute respiratory syndrome 2 (SARS-CoV-2) recombinant spike protein variants on platelet morphology activation. Citrated whole blood collected from ostensibly healthy subjects challenged with saline (control sample) 20 ng/mL final concentration SARS-CoV-2 Ancestral, Alpha, Delta, Omicron variants. Platelet count found be decreased all concentrations tested, achieving lowest values Delta protein. The mean volume increased samples irrespective but especially using Alpha proteins. both function analyzer-200 collagen-adenosine diphosphate collagen-epinephrine thus reflecting exhaustion, displaying again higher increases Most where proteins were added flagged as containing clumps. Morphological analysis revealed presence considerable number activated platelets, clumps, platelet-monocyte, platelet-neutrophils aggregates, spiked at ng/mL. These results provide support evidence that is capable activating platelets through its protein, though such effect varies depending

Language: Английский

---

Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: May 9, 2025

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease 2019 (COVID-19) pandemic, continues to pose global health challenges despite availability of approved vaccines and antiviral drugs. The emergence new variants SARS-CoV-2 ongoing post-COVID complications necessitate continuous exploration effective treatments. Kaurenoic acid (KA) a tetracyclic diterpenoid isolated from plants Copaifera genus has been previously recognized its anti-inflammatory, antibacterial, antifungal, antitumor properties. However, there lack knowledge about in vitro effects KA on viruses. Here, we evaluated effect replication first time. Methods Results demonstrated high selective index 16.1 against robust effectiveness B.1.617.2 (Delta) BA.2 (Omicron) variants. Mechanistically, was shown impair post-entry steps viral replication. In subgenomic replicon system, observed decrease RNA synthesis different cell lines. Using an infectious virus, larger reduction release virions observed. We suggest that interacts with proteases through molecular docking. Conclusion conclusion, emerges as inhibitor and, consequently, cycle. It could be good candidate further investigation clinical assays infection.

Language: Английский

---

Fujirebio Lumipulse SARS-CoV-2 antigen immunoassay: pooled analysis of diagnostic accuracy

Diagnosis, Journal Year: 2022, Volume and Issue: 9(2), P. 149 - 156

Published: March 15, 2022

Abstract We provide here a pooled analysis of accuracy Fujirebio Lumipulse SARS-CoV-2 Antigen chemiluminescent immunoassay for diagnosing acute infections. An electronic search was conducted in Scopus and Medline with the keywords “Lumipulse” AND “antigen” “SARS-CoV-2” or “COVID-19”, up to January 21, 2022, identifying clinical investigations (minimum sample size ≥100) where diagnostic G Ag tested against reference molecular techniques. All studies which allowed construct 2 × table were included analysis. A final number 21 studies, totalling 17,648 nasopharyngeal 8538 saliva specimens, finally included. The sensitivity specificity swabs 0.80 (95%CI, 0.78–0.81) 0.98 0.97–0.98), respectively, whilst area under curve agreement 0.980 0.973–0.986) 94.9%, respectively. In twelve used fixed 1.34 pg/mL currently recommended manufacturer’s threshold, remained unvaried. samples, 0.75 0.71–0.75) 1.00 0.99–1.00), 0.976 0.969–0.984) 98.4%, five 0.67 conclusion, assay demonstrates good specificity, thus representing valuable complementary integrative option testing current pandemic.

Language: Английский

---

Ad interim recommendations for diagnosing SARS-CoV-2 infection by the IFCC SARS-CoV-2 variants working group

Clinical Chemistry and Laboratory Medicine (CCLM), Journal Year: 2022, Volume and Issue: 60(7), P. 975 - 981

Published: April 22, 2022

Abstract This document, endorsed by the IFCC Working Group on SARS-CoV-2 Variants, aims to update previous indications for diagnosing acute infection, taking into consideration evidence that has emerged after origin and spread of new lineages sub-lineages virus characterized mutated genetics altered biochemical, biological clinical characteristics. These encompass use different diagnostic strategies in specific settings, such as high risk infection (symptomatic patients), low (asymptomatic subjects) at hospital admission/contact tracing, testing asymptomatic subjects, epidemiologic surveys and/or population screening, along with tentative identification SARS-CoV-2.

Language: Английский

---

Cardiovascular outcomes between COVID-19 and non-COVID-19 pneumonia: a nationwide cohort study

BMC Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Oct. 20, 2023

Previous studies that assessed the risk of cardiovascular outcomes in survivors coronavirus disease 2019 (COVID-19) were likely limited by lack generalizability and selection controls nonrepresentative a counterfactual situation regarding COVID-19-related hospitalization. This study determined whether COVID-19 hospitalization was associated with incident compared to non-COVID-19 pneumonia hospitalization.Nationwide population-based conducted using Korean National Health Insurance Service database. A cohort 132,784 inpatients (October 8, 2020-September 30, 2021) 31,173 (January 1-December 31, 2019) included. The primary outcome major adverse event (MACE; composite myocardial infarction stroke). Hazard ratios (HRs) 95% confidence intervals (CIs) all interest estimated between inverse probability treatment-weighted patients pneumonia.After weighting, groups included 125,810 (mean [SD] age, 47.2 [17.6] years; men, 49.3%) 28,492 48.6 [18.4] 47.2%), respectively. not an increased MACE (HR, 0.84; CI 0.69-1.03). However, 7.30; 3.29-16.21), dysrhythmia 1.88; 1.04-3.42), acute myocarditis 11.33; 2.97-43.20), 6.78; 3.03-15.15), congestive heart failure 1.95; 1.37-2.77), thrombotic 8.26; 4.06-16.83) risks significantly higher aged 18-39 years. findings consistent after adjustment for preexisting disease. conferred 6.47; 2.53-16.52) or deep vein thrombosis 1.97; 1.38-2.80), regardless vaccination status.Hospitalized at pneumonia. Further are needed evaluate is confined younger patients.

Language: Английский

---

COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress

Cancers, Journal Year: 2022, Volume and Issue: 14(15), P. 3711 - 3711

Published: July 29, 2022

The majority of publications regarding SARS-CoV-2 infections in adult patients with acute leukemia (AL) refer to hematological general and are not focused on myeloid (AML) or lymphoblastic (ALL). We herein report a review the current literature AL infected SARS-CoV-2. Overall, SARS-CoV-2-associated mortality ranges from 20-52% AL. AML have particularly high COVID-19-related mortality. Of note, most available data relate pre-vaccination era variants before Omicron. impact COVID-19 treatment is rarely reported. Based few studies available, delay does appear be associated an increased risk relapse, whereas therapy discontinuation was worse outcomes patients. Therefore, recommendations suggest delaying systemic SARS-CoV-2-positive until negativity, if immediate required. It recommended offer vaccination all patients; reported antibody responses around 80-96%. Seronegative should additionally receive prophylactic administration anti-SARS-CoV-2 monoclonal antibodies. Patients treated early antiviral prevent disease progression enable rapid elimination virus.

Language: Английский

---